HANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million

Bulletin Express07-08

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 33,800 H shares on 8 July 2026 via on-exchange transactions. The highest price paid per share was HKD 30.00 and the lowest was HKD 28.42, for a total consideration of HKD 0.98 million.

\n\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell from 134.41 million to 134.37 million, representing a 0.025% reduction. Treasury shares rose to 1.84 million, while total issued shares remained unchanged at 136.22 million.

\n\nThe repurchase forms part of the mandate approved on 24 June 2026, which allows the company to buy back up to 13.47 million shares. Cumulative repurchases under this authority now stand at 322,600 shares, equal to 0.2395% of the issued share count on the mandate date.

\n\nUnder Hong Kong Stock Exchange rules, HANXBIO-B is subject to a moratorium on new share issues or treasury-share sales until 7 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182460843?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 20:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182460843","market":"us","top_or_hot":-1,"title":"HANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 33,800 H shares on 8 July 2026 via on-exchange transactions. The highest price paid per share was HKD 30.00 and the lowest was HKD 28.42, for a total consideration of HKD 0.98 million.</p>\n<p>\\n\\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell from 134.41 million to 134.37 million, representing a 0.025% reduction. Treasury shares rose to 1.84 million, while total issued shares remained unchanged at 136.22 million.</p>\n<p>\\n\\nThe repurchase forms part of the mandate approved on 24 June 2026, which allows the company to buy back up to 13.47 million shares. Cumulative repurchases under this authority now stand at 322,600 shares, equal to 0.2395% of the issued share count on the mandate date.</p>\n<p>\\n\\nUnder Hong Kong Stock Exchange rules, HANXBIO-B is subject to a moratorium on new share issues or treasury-share sales until 7 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Repurchases 33,800 H Shares on 8 July, Treasury Stock Increases to 1.84 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-08 20:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 33,800 H shares on 8 July 2026 via on-exchange transactions. The highest price paid per share was HKD 30.00 and the lowest was HKD 28.42, for a total consideration of HKD 0.98 million.</p>\n<p>\\n\\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell from 134.41 million to 134.37 million, representing a 0.025% reduction. Treasury shares rose to 1.84 million, while total issued shares remained unchanged at 136.22 million.</p>\n<p>\\n\\nThe repurchase forms part of the mandate approved on 24 June 2026, which allows the company to buy back up to 13.47 million shares. Cumulative repurchases under this authority now stand at 322,600 shares, equal to 0.2395% of the issued share count on the mandate date.</p>\n<p>\\n\\nUnder Hong Kong Stock Exchange rules, HANXBIO-B is subject to a moratorium on new share issues or treasury-share sales until 7 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1182460843","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182460843","pubTimestamp":1783514773,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 33,800 H shares on 8 July 2026 via on-exchange transactions. The highest price paid per share was HKD 30.00 and the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉思生物-B于7月8日回购33,800股H股，库存股增至184万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed that it bought back 33,800 H shares on 8 July 2026 via on-exchange transactions. The highest price paid per share was HKD 30.00 and the lowest was HKD 28.42, for a total consideration of HKD 0.98 million.\n\\n\\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell from 134.41 million to 134.37 million, representing a 0.025% reduction. Treasury shares rose to 1.84 million, while total issued shares remained unchanged at 136.22 million.\n\\n\\nThe repurchase forms part of the mandate approved on 24 June 2026, which allows the company to buy back up to 13.47 million shares. Cumulative repurchases under this authority now stand at 322,600 shares, equal to 0.2395% of the issued share count on the mandate date.\n\\n\\nUnder Hong Kong Stock Exchange rules, HANXBIO-B is subject to a moratorium on new share issues or treasury-share sales until 7 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182460843","isCrawlerRequest":true}